INNOVIVA, INC. Long-Term Debt
INNOVIVA, INC. (INVA) had Long-Term Debt of $258.45 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Noncurrent
us-gaap:LongTermDebtNoncurrent · last filed 2026-08-05
- 2026-06-30: Long-term Debt, Excluding Current Maturities $258.45M.
- 2026-03-31: Long-term Debt, Excluding Current Maturities $258.10M.
- 2025-12-31: Long-term Debt, Excluding Current Maturities $257.73M.
- 2025-09-30: Long-term Debt, Excluding Current Maturities $257.38M.
| Period end | Long-term Debt, Excluding Current Maturities |
|---|---|
| 2026-06-30 | $258.45M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $258.10M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $257.73M 10-Q · filed 2026-08-05 |
| 2025-09-30 | $257.38M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $257.02M 10-Q · filed 2025-08-06 |
| 2025-03-31 | $256.67M 10-Q · filed 2025-05-07 |
| 2024-12-31 | $256.32M 10-K · filed 2026-02-25 |
| 2024-09-30 | $255.97M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $447.28M 10-Q · filed 2024-07-31 |
| 2024-03-31 | $446.76M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $446.23M 10-K · filed 2025-02-26 |
| 2023-09-30 | $445.72M 10-Q · filed 2023-11-01 |
| 2023-06-30 | $445.20M 10-Q · filed 2023-08-02 |
| 2023-03-31 | $444.69M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $444.18M 10-K/A · filed 2024-03-05 |
| 2022-09-30 | $443.68M 10-Q · filed 2022-11-09 |
| 2022-06-30 | $443.18M 10-Q · filed 2022-07-27 |
| 2022-03-31 | $442.73M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $394.65M 10-K · filed 2023-02-28 |
| 2021-09-30 | $392.30M 10-Q · filed 2021-10-27 |
| 2021-06-30 | $389.99M 10-Q · filed 2021-07-29 |
| 2021-03-31 | $387.73M 10-Q · filed 2021-04-28 |
| 2020-12-31 | $385.52M 10-K/A · filed 2022-03-17 |
| 2020-09-30 | $383.35M 10-Q · filed 2020-10-28 |
| 2020-06-30 | $381.23M 10-Q · filed 2020-07-29 |
| 2020-03-31 | $379.15M 10-Q · filed 2020-04-29 |
| 2019-12-31 | $377.12M 10-K · filed 2021-02-25 |
| 2019-09-30 | $388.64M 10-Q · filed 2019-10-30 |
| 2019-06-30 | $386.68M 10-Q · filed 2019-07-24 |
| 2019-03-31 | $384.74M 10-Q · filed 2019-05-01 |
| 2018-12-31 | $382.86M 10-K · filed 2020-02-19 |
| 2018-09-30 | $381.00M 10-Q · filed 2018-10-31 |
| 2018-06-30 | $486.53M 10-Q · filed 2018-07-26 |
| 2018-03-31 | $484.59M 10-Q · filed 2018-05-04 |
| 2017-12-31 | $574.36M 10-K · filed 2019-02-19 |
| 2017-09-30 | $578.45M 10-Q · filed 2017-11-03 |
| 2017-06-30 | $638.71M 10-Q · filed 2017-08-08 |
| 2017-03-31 | $702.33M 10-Q · filed 2017-05-05 |
| 2016-12-31 | $708.34M 10-K · filed 2018-02-23 |
| 2016-09-30 | $719.45M 10-Q · filed 2016-11-03 |
| 2016-06-30 | $722.29M 10-Q · filed 2016-08-04 |
| 2016-03-31 | $734.51M 10-Q · filed 2016-05-05 |
| 2015-12-31 | $733.13M 10-K · filed 2017-02-28 |
| 2015-09-30 | $744.09M 10-Q · filed 2015-11-05 |
| 2015-06-30 | $738.47M 10-Q · filed 2015-08-06 |
| 2015-03-31 | $732.06M 10-Q · filed 2015-05-08 |
| 2014-12-31 | $725.64M 10-Q · filed 2015-11-05 |
| 2014-09-30 | $705.11M 10-Q · filed 2014-11-04 |
| 2013-12-31 | $287.50M 10-Q · filed 2014-11-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |